Description
AOD-9604 is a 16-residue synthetic peptide modelled on the C-terminal end of human growth hormone, the region linked to fat metabolism in early hormone research. Developed at Monash University in Melbourne, it is a reference compound in adipocyte and lipid-metabolism studies. Pure Peptides Canada supplies it as a lyophilized research reagent in 5 mg vials, with an independent Janoshik HPLC and mass-spectrometry report, CAD pricing and tracked shipping from inside Canada.
AOD-9604 at a glance
- What it is: hGH(177-191) with an added N-terminal tyrosine and an internal disulfide bridge, designed to study GH’s fat-metabolism region apart from the rest of the hormone.
- What researchers study: lipolysis and lipogenesis in fat cells, effects separated from IGF-1 and glucose signalling, and cartilage models.
- Evidence level: cell and animal work plus Phase 2 human trials. A large 2007 obesity trial did not beat placebo, and it was never approved as a drug.
- Supplied as: sealed lyophilized powder, 5 mg, single vial or box of 10.
- Delivery: ships from inside Canada by tracked Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299.
AOD-9604
Tyr-hGH(177-191) · Anti-Obesity Drug 9604 · modified hGH fragment
- Y
- L
- R
- I
- V
- Q
- C
- R
- S
- V
- E
- G
- S
- C
- G
- F
Blue: added N-terminal tyrosine. Dashed: the two cysteines joined by a disulfide bridge.
- Length
- 16 amino acids, one disulfide bond
- Molecular formula
- C78H123N23O23S2
- Molecular weight
- ≈ 1815 g/mol
- CAS number
- 221231-10-3
- Form
- Lyophilized powder, sealed vial
- Sizes
- 5 mg (single or box of 10)
- SKU
- PP-AOD9604
Where the evidence stands
- Cell studies
- Animal models
- Controlled human trials
- Approved medicine
Phase 2 obesity trials did not show a significant benefit over placebo. AOD-9604 is not an approved drug.
What is AOD-9604?
Growth hormone affects both growth and fat metabolism. In the 1990s, Frank Ng and colleagues at Monash University worked on separating those effects and found that the C-terminal region of the hormone carried much of the fat-metabolism activity. AOD-9604 is a stabilized version of that region, residues 177 to 191 with an added tyrosine. Metabolic Pharmaceuticals in Melbourne then developed it as a potential obesity drug.
In mice it increased fat breakdown and reduced fat formation without raising IGF-1 or blood glucose, the effects that limit full-length growth hormone. Human results were less encouraging: a large Phase 2b trial reported in 2007 found no significant weight loss compared with placebo, and the obesity programme was dropped. Researchers have since studied it in cartilage and joint models. It is closely related to HGH Fragment 176-191.
What AOD-9604 research looks at
- Adipocyte metabolism: lipolysis and lipogenesis in isolated fat cells and tissue.
- Separating GH effects: metabolic activity without IGF-1, insulin or growth signalling.
- Beta-adrenergic pathways: the receptor systems proposed to mediate its fat-cell effects.
- Cartilage models: joint and cartilage repair studies in animals.
- Fragment comparisons: side-by-side work with HGH Fragment 176-191.
Regulatory status: AOD-9604 is not an authorized drug in Canada, and it is prohibited by the World Anti-Doping Agency. We sell it strictly as a laboratory reagent for in-vitro research.
Why researchers order AOD-9604 from Pure Peptides Canada
Add a 5 mg vial or a box of 10 above. Orders over $299 ship free across Canada.
See lab resultsChecking an AOD-9604 identity report
Use these values when you open the mass-spectrometry result for an AOD-9604 peptide batch. They are calculated from the sequence YLRIVQCRSVEGSCGF, with a free C-terminal acid and one disulfide bond between the two cysteines (C78H123N23O23S2):
- Monoisotopic mass: 1813.86 Da (average molecular weight about 1815.1 g/mol).
- Expected ions: [M+H]+ at m/z 1814.87. Electrospray spectra of a peptide this size often show multiply charged ions as well: [M+2H]2+ at m/z 907.94 and [M+3H]3+ at m/z 605.63.
- Disulfide check: the open (reduced) chain is 2.02 Da heavier, with [M+H]+ at m/z 1816.88. That overlaps the normal isotope pattern, so judge it from the shape of the whole isotope cluster rather than from a single peak.
Read the peptide mass spectrum guide for a worked explanation of isotope clusters; the Janoshik report for AOD-9604 is listed on our Lab Testing page.
AOD-9604 FAQ
Where can I buy AOD-9604 in Canada?
Pure Peptides Canada stocks AOD-9604 as a lyophilized research reagent in 5 mg vials and ships it from inside Canada by tracked Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299.
What is the difference between AOD-9604 and HGH Fragment 176-191?
They are closely related. Both are based on the C-terminal end of human growth hormone. AOD-9604 is the specific stabilized version, Tyr-hGH(177-191), developed and trialled by Metabolic Pharmaceuticals. The identity mass on each lab report confirms which molecule is in the vial.
Did AOD-9604 work in human trials?
Not for its original purpose. A large Phase 2b obesity trial reported in 2007 found no significant weight loss compared with placebo, and development as an obesity drug stopped. Our AOD-9604 research guide covers the trial history.
Is this AOD-9604 third-party tested?
Yes. An HPLC purity and mass-spectrometry identity report from Janoshik Analytical, an independent lab, is listed on our Lab Testing page. Our COA guide explains how to read it.
Is AOD-9604 approved in Canada?
No. AOD-9604 is not an authorized drug in Canada. It is sold here only as a laboratory reagent for in-vitro research.
Can AOD-9604 be used in people or animals?
No. It is for in-vitro laboratory research only and is not a drug, supplement or food. We do not provide dosing or administration information.
For laboratory research use only. Not a drug, supplement, food or cosmetic, not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Olivia Stewart –
Fast delivery. Product as advertised. Will buy again, and order some others on my wish list.